U.S. markets open in 25 minutes

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0000+0.0400 (+4.17%)
At close: 4:00PM EDT

0.9900 -0.01 (-1.00%)
Before hours: 8:16AM EDT

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Leonard L. MazurExec. Chairman & Sec.363.75kN/A1945
Mr. Myron Z. HolubiakPres, CEO & Director654.75kN/A1947
Mr. Jaime BartushakCFO & Chief Accounting Officer395.56kN/A1968
Mr. Gary F. TalaricoExec. VP of OperationsN/AN/A1955
Mr. Andrew ScottVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction tissue expander infections following breast reconstructive surgeries; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Corporate Governance

Citius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.